| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 | 6,622 | 6,147 | 6,892 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 | 4,485 | 4,142 | 5,133 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 | 2,137 | 2,005 | 1,759 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % | 31 % | 31 % | 24 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 | 400 | 449 | 331 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 |
Zydus Life Science
Zydus Life Science
913.05
-1.60
(-0.17%)
Market Cap
91,874.19 Cr
PE Ratio
18.31
Volume
4,56,550.00
Day High - Low
919.50 - 905.80
52W High-Low
1,059.05 - 795.00
Key Fundamentals
Market Cap
91,874.19 Cr
EPS
44.97
PE Ratio
18.31
PB Ratio
3.64
Book Value
251.45
EBITDA
7,328.00
Dividend Yield
1.20 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
17.51
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from28 analysts
Actual
Company News
View All News
Zydus Lifesciences receives final USFDA approvals for Ivermectin and Dapsone tablets, targeting combined annual US market of USD 23.2 million. Company now holds 434 total approvals.
Zydus Lifesciences successfully develops pembrolizumab biosimilar FYB206 with positive bioequivalence data to Keytruda, preparing for USFDA filing to expand oncology portfolio.
Zydus Lifesciences is preparing to launch semaglutide injection in India coinciding with patent expiry, positioning itself in the diabetes and weight management market.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,799.40 | #1 4,31,736.33 | 39.06 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 66.49 | |
6,329.00 | 1,68,015.06 | 68.15 | 9,712.00 | 18.67 | 2,191 | -1.02 | 52.54 | |
4,317.80 | 1,46,133.97 | 64.85 | 11,539.40 | 6.99 | 1,911 | 26.24 | 60.63 | |
1,303.80 | 1,08,819.11 | 19.84 | 33,741.20 | 16.73 | 5,725 | -15.28 | 58.49 | |
2,343.80 | 1,07,064.50 | 22.83 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 71.29 | |
1,321.20 | 1,06,722.81 | 23.63 | 28,409.50 | 7.12 | 5,291 | -57.18 | 41.65 | |
913.05 | #7 91,874.19 | #1 18.31 | #5 23,511.00 | #3 18.55 | #4 4,615 | #7 -0.32 | 51.93 | |
2,187.00 | 90,280.47 | 50.95 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 54.90 | |
1,231.90 | 71,548.95 | 20.43 | 32,345.60 | 9.43 | 3,484 | 7.59 | 59.24 | |
5,530.00 | 66,119.45 | 27.37 | 13,458.30 | 3.70 | 2,216 | 1.90 | 46.88 |
Growth Rate
Revenue Growth
18.55 %
Net Income Growth
20.45 %
Cash Flow Change
109.94 %
ROE
0.98 %
ROCE
7.64 %
EBITDA Margin (Avg.)
9.06 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 | 13,134 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 | 17,046 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 | 6,408 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 | 14,968 |
| Total Equity & Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 | 9,042 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 | 1,802 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 | 26,358 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,853 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 2,373 | -534 | -75 | 414 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,012 | -835 | 1,137 | 1,178 | -1,492 | -8,377 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,505 | 3,293 | 2,104 | 2,689 | 3,228 | 6,777 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,094 | -2,549 | -868 | -4,400 | -1,810 | 2,014 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % | 74.99 % | 74.99 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % | 7.13 % | 7.34 % | 7.06 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % | 11.13 % | 10.86 % | 11.09 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % | 5.46 % | 5.49 % | 5.54 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % | 1.28 % | 1.32 % | 1.31 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 | 4,03,266 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 11 | 0.00 |
| Dividend Yield (%) | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 1.2 | 0.00 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2026
Feb 19, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2026
Feb 19, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 15, 2026
Feb 15, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2026
Feb 14, 2026Update On LitigationFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 09, 2026
Feb 09, 2026Board Comments On Penalties Levied By BSE And NSEFeb 09, 2026
Feb 09, 2026Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2025Feb 09, 2026
Feb 09, 2026Board Meeting Outcome for Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2025Feb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 31, 2026
Jan 31, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 30, 2026
Jan 30, 2026Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2025.Jan 27, 2026
Jan 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2026
Jan 23, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 22, 2026
Jan 22, 2026Revision In ESG RatingJan 20, 2026
Jan 20, 2026UpdateJan 17, 2026
Jan 17, 2026Closing Of AcquisitionJan 15, 2026
Jan 15, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 15, 2026
Jan 15, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 13, 2026
Jan 13, 2026UpdateJan 10, 2026
Jan 10, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Jan 07, 2026UpdatesJan 02, 2026
Jan 02, 2026Receipt Of Demand Order-In-Original From Assistant Commissioner Of State Tax GujaratDec 30, 2025
Dec 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 27, 2025
Dec 27, 2025Intimation Of ESG RatingDec 26, 2025
Dec 26, 2025Closure of Trading WindowDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 24, 2025
Dec 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 23, 2025
Dec 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 19, 2025
Dec 19, 2025Intimation Of ESG RatingDec 16, 2025
Dec 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 15, 2025
Dec 15, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 12, 2025
Dec 12, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 12, 2025
Dec 12, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 12, 2025
Dec 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 10, 2025
Dec 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 09, 2025
Dec 09, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 52.48
ATR(14)
Volatile 19.69
STOCH(9,6)
Neutral 49.59
STOCH RSI(14)
Oversold 13.75
MACD(12,26)
Bullish 0.15
ADX(14)
Strong Trend 25.58
UO(9)
Bearish 55.54
ROC(12)
Uptrend And Accelerating 0.46
WillR(14)
Neutral -56.19
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care,...more
Listing Date
27 Apr, 2000(25 Years,
7 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
